PMID- 20884422
OWN - NLM
STAT- MEDLINE
DCOM- 20110322
LR  - 20161125
IS  - 1969-6213 (Electronic)
IS  - 1774-024X (Linking)
VI  - 6
IP  - 3
DP  - 2010 Aug
TI  - Intravenous enoxaparin versus unfractionated heparin in unselected patients 
      undergoing percutaneous coronary interventions: the Zurich enoxaparin versus 
      unfractionated heparin in PCI study (ZEUS).
PG  - 407-12
LID - EIJV6I3A67 [pii]
LID - 10.4244/EIJV6I3A67 [doi]
AB  - AIMS: To evaluate the efficacy and safety of intravenous enoxaparin as an 
      alternative to unfractionated heparin (UFH) as antithrombotic therapy in 
      unselected patients undergoing percutaneous coronary intervention (PCI). METHODS 
      AND RESULTS: Eight hundred and seventy-six (876) consecutive eligible patients 
      undergoing PCI were prospectively randomised to either intravenous enoxaparin 
      0.75 mg/kg or dose-adjusted UFH in this open-label study that was prematurely 
      stopped due to slow recruitment. Randomisation was stratified on elective PCI or 
      PCI for acute coronary syndrome (ACS). The primary endpoint was a combination of 
      death, myocardial infarction, unplanned target vessel revascularisation and major 
      bleeding at 30 days. Secondary endpoint was a composite of major and minor 
      bleeding and thrombocytopenia < 50x109. The primary endpoint of intravenous 
      enoxaparin did not differ from those of UFH (5.5% vs. 7.0%, p=ns) whereas safety 
      endpoints were reduced with enoxaparin compared to UFH (9.9% vs. 20.0%, p<0.001). 
      Among 229 (26%) patients presenting with ACS, the incidence of both, the primary 
      and secondary endpoints, was lower with enoxaparin as compared to UFH (1.8% vs. 
      12.9% and 14.2% vs. 31%, p<0.001 and p=0.003, respectively). CONCLUSIONS: Due to 
      the premature halting of the study and the low event rate, these data are 
      observational only, and no definite conclusion could be made concerning efficacy 
      and safety of intravenous enoxaparin as an alternative to UFH in unselected 
      patients undergoing PCI.
FAU - Bertel, Osmund
AU  - Bertel O
AD  - HerzGefassZentrum Zurich, Klinik Im Park, Switzerland. 
      osmund.bertel@hirslanden.ch
FAU - Ramsay, David
AU  - Ramsay D
FAU - Wettstein, Tobias
AU  - Wettstein T
FAU - Kurz, David J
AU  - Kurz DJ
FAU - Stettler, Irene
AU  - Stettler I
FAU - Straumann, Edwin
AU  - Straumann E
FAU - Frielingsdorf, Juergen
AU  - Frielingsdorf J
FAU - Maurer, Dominik
AU  - Maurer D
FAU - Naegeli, Barbara
AU  - Naegeli B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - EuroIntervention
JT  - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on 
      Interventional Cardiology of the European Society of Cardiology
JID - 101251040
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Coronary Artery Disease/diagnostic imaging/*therapy
MH  - Dose-Response Relationship, Drug
MH  - Enoxaparin/*administration & dosage
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage
MH  - Follow-Up Studies
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Radiography
MH  - Switzerland
MH  - Treatment Outcome
EDAT- 2010/10/05 06:00
MHDA- 2011/03/23 06:00
CRDT- 2010/10/02 06:00
PHST- 2010/10/02 06:00 [entrez]
PHST- 2010/10/05 06:00 [pubmed]
PHST- 2011/03/23 06:00 [medline]
AID - EIJV6I3A67 [pii]
AID - 10.4244/EIJV6I3A67 [doi]
PST - ppublish
SO  - EuroIntervention. 2010 Aug;6(3):407-12. doi: 10.4244/EIJV6I3A67.